Telomir Pharmaceuticals (NASDAQ:TELO) Now Covered by Analysts at Rodman & Renshaw

Equities research analysts at Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals (NASDAQ:TELO) in a report issued on Friday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. Rodman & Renshaw’s price target suggests a potential upside of 258.85% from the company’s current price.

Telomir Pharmaceuticals Stock Performance

NASDAQ TELO opened at $4.18 on Friday. The firm’s 50 day moving average price is $4.56 and its two-hundred day moving average price is $4.85. Telomir Pharmaceuticals has a twelve month low of $3.11 and a twelve month high of $9.54. The stock has a market cap of $124.41 million and a price-to-earnings ratio of -7.21.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its quarterly earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). On average, research analysts forecast that Telomir Pharmaceuticals will post -0.4 EPS for the current fiscal year.

Institutional Trading of Telomir Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Nuveen Asset Management LLC acquired a new position in Telomir Pharmaceuticals in the 4th quarter valued at approximately $103,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Telomir Pharmaceuticals by 279.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company’s stock valued at $44,000 after acquiring an additional 7,879 shares in the last quarter. Gotham Asset Management LLC acquired a new position in shares of Telomir Pharmaceuticals in the fourth quarter worth $28,000. Bank of America Corp DE raised its holdings in shares of Telomir Pharmaceuticals by 283.9% during the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after acquiring an additional 10,880 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Telomir Pharmaceuticals by 211.5% during the fourth quarter. Northern Trust Corp now owns 151,628 shares of the company’s stock valued at $625,000 after purchasing an additional 102,948 shares during the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.